NCT04717375

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

TERMINATEDPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2021-04-11Est. Completion: 2025-07-02

Enrollment target: 125 participants

Locations

Mayo Clinic Hospital- Site Number : 8400003, Phoenix, Arizona, United States
City of Hope Comprehensive Cancer Center- Site Number : 8400002, Duarte, California, United States
University of Colorado- Site Number : 8400012, Aurora, Colorado, United States
Smilow Cancer Center at Yale-New Haven- Site Number : 8400001, New Haven, Connecticut, United States
Clermont Oncology Center- Site Number : 8400005, Clermont, Florida, United States
Mid Florida Hematology and Oncology Center- Site Number : 8400006, Orange City, Florida, United States
Mercy Cancer Center - MercyOne Richard Deming Cancer Center- Site Number : 8400011, Des Moines, Iowa, United States
Norton Cancer Institute - Downtown Women's Cancer Center- Site Number : 8400004, Louisville, Kentucky, United States
Mayo Clinic Hospital Rochester- Site Number : 8400007, Rochester, Minnesota, United States
Investigational Site Number : 1240001, Barrie, Ontario, Canada
Investigational Site Number : 1240003, Sherbrooke, Quebec, Canada
Investigational Site Number : 3760004, Haifa, Israel
Investigational Site Number : 3760005, Jerusalem, Israel

Ovarian Cancer RecurrentOvarian CancerPlatinum Resistant Ovarian Cancer

The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and als…

Detroit, United StatesCompleted Sep 30, 2026

Lung NeoplasmsNeoadjuvant TherapyImmunotherapyMinimal Residual Disease

This study is a prospective single-arm clinical trial targeting patients with stage IB-IIIA non-small cell lung cancer (…

Beijing, ChinaEst. completion Oct 31, 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.